| Literature DB >> 29146013 |
A Mekinian1, N Costedoat-Chalumeau2, L Carbillon3, A Coulomb-L'Hermine4, V Le Guern2, A Masseau5, E Lazaro6, J Cohen7, M Bornes7, G Kayem8, O Fain9.
Abstract
Chronic intervillositis is a rare condition, which is associated with severe obstetrical outcome and high recurrence rate. Obstetrical adverse events are intrauterine growth restriction, recurrent early miscarriages, intrauterine deaths and prematurity by placental insufficiency. The determination of the extension and the intensity of the chronic intervillositis are not currently standardized. High rates of recurrence have been described, but actually there is no reliable predictive biomarker. No treatment is currently validated, but the use of immunomodulatory drugs could be justified by the possible autoimmune or allo-immune origin. The treatment should be particularly discussed in patients with recurrent and severe obstetrical adverse events and in the presence of severe and massive histological lesions.Entities:
Keywords: Associated autoimmune diseases; Chronic intervillositis; Intervillites; Maladies associées; Outcome; Pronostic; Traitement; Treatment
Mesh:
Substances:
Year: 2017 PMID: 29146013 DOI: 10.1016/j.revmed.2017.10.422
Source DB: PubMed Journal: Rev Med Interne ISSN: 0248-8663 Impact factor: 0.728